Cost of Ozempic, Wegovy, Zepbound, and Mounjaro: What You Will Actually Pay in 2025

What Does Ozempic Cost Without Insurance?

Ozempic (semaglutide injection, Novo Nordisk) carries a 2025 U.S. list price of approximately $969 per 28-day supply across all available doses: 0.25 mg, 0.5 mg, 1 mg, and 2 mg. The package contains four prefilled pens. That price does not change much by dose because the pen fill volume adjusts rather than the pen count, which means a patient dose-escalating from 0.5 mg to 2 mg pays roughly the same sticker price each month.

Ozempic is FDA-approved for glycemic control in adults with type 2 diabetes and to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It is not FDA-approved for obesity as a standalone indication, which matters significantly for insurance purposes. The SELECT trial (N=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo over a median 34.2 months, with a hazard ratio of 0.80 (95% CI 0.72 to 0.90, P<0.001) [1].

Novo Nordisk's NovoCare savings program offers a monthly copay of $25 for commercially insured patients who meet eligibility criteria. Without any coverage, most patients pay the full ~$969. Some specialty pharmacies and warehouse clubs (Costco, Mark Cuban's Cost Plus Drugs) list semaglutide vials at somewhat lower prices for specific formulations, though the branded pen devices remain near list.

What Does Wegovy Cost Without Insurance?

Wegovy (semaglutide 2.4 mg, Novo Nordisk) has a 2025 list price of approximately $1,349 per 28-day supply at the 2.4 mg maintenance dose. Lower doses used during the 16-week titration period (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) list at roughly the same price per month, so the annual cost at maintenance is close to $16,200 out of pocket without assistance.

STEP-1 (N=1,961) demonstrated that semaglutide 2.4 mg produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) [2]. STEP-5 (N=304) extended follow-up to 104 weeks and showed the 14.8% weight loss was maintained, with 77.1% of participants achieving at least 5% weight loss [3]. These are the efficacy data that justify the price in clinical terms. The Wegovy FDA label specifies it for adults with BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity [4].

Novo Nordisk offers a Wegovy savings card that brings monthly cost to $0 for eligible commercially insured patients, subject to annual program caps. Patients whose insurance denies coverage and who do not qualify for the savings card face the full $1,349. Medicare Part D is excluded by federal statute from covering anti-obesity medications, a policy that the American Diabetes Association has called for Congress to revise [5].

What Does Mounjaro Cost Without Insurance?

Mounjaro (tirzepatide, Eli Lilly) lists at approximately $1,069 per 28-day supply across its six available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Mounjaro is FDA-approved for glycemic control in adults with type 2 diabetes. Like Ozempic, it carries a diabetes label, not an obesity label, which affects insurance behavior.

SURMOUNT-2 (N=938) enrolled adults with type 2 diabetes and showed tirzepatide 15 mg produced a mean weight reduction of 15.7% at 72 weeks versus 3.3% with placebo [6]. The dual GIP/GLP-1 receptor agonism of tirzepatide is believed to explain why weight outcomes exceed those seen with GLP-1-only agents, though head-to-head randomized trial data against semaglutide remain limited.

Eli Lilly's Savings Card program offers Mounjaro for as low as $25 per month for eligible commercially insured patients. LillyDirect, the manufacturer's direct pharmacy program, also provides pricing options that can reduce out-of-pocket cost for self-pay patients, though prices vary. Patients without commercial insurance or savings card eligibility pay closer to the $1,069 list price.

What Does Zepbound Cost Without Insurance?

Zepbound (tirzepatide, Eli Lilly) is the obesity-specific brand of the same tirzepatide molecule. It lists at approximately $1,059 per 28-day supply, slightly lower than Mounjaro at equivalent doses. Zepbound is FDA-approved for chronic weight management in adults with BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity [7].

SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced a mean body weight reduction of 22.5% at 72 weeks versus 2.4% with placebo (P<0.001) [8]. SURMOUNT-4 (N=670) showed that patients who stopped tirzepatide after 36 weeks regained 14% of body weight by week 88, while those who continued lost an additional 5.5%, illustrating the need for long-term treatment [9].

Eli Lilly offers Zepbound vials (not pens) through LillyDirect at $349 per month for the 2.5 mg and 5 mg doses, and $499 per month for 7.5 mg through 15 mg, as a self-pay option. This is a meaningful reduction from the pen list price and is available to patients without insurance coverage. The vials require drawing up and self-injecting using a separate syringe, which some patients find less convenient than the autoinjector pens.

How Does Insurance Coverage Work for These Medications?

Insurance coverage splits sharply along the diabetes-versus-obesity line. Most commercial health plans cover Ozempic and Mounjaro when prescribed for type 2 diabetes because they are classified as antidiabetic agents. Coverage requires a prior authorization that confirms the diagnosis, typically HbA1c above a threshold (often 7.5% or higher, depending on the plan), documented failure of at least one first-line agent like metformin, and a valid ICD-10 code.

Wegovy and Zepbound are classified as anti-obesity medications. The majority of commercial plans exclude them or require a separate obesity-specific benefit rider, which most employer plans do not carry. The AACE/ACE obesity clinical practice guidelines state that obesity is a disease requiring evidence-based medical treatment [10], but plan formulary decisions do not follow clinical guidelines automatically.

Medicare Part D is prohibited by federal statute (the Medicare Modernization Act of 2003) from covering anti-obesity medications except when prescribed for a comorbid condition like type 2 diabetes. A 2024 proposed rule from CMS would have allowed Part D coverage for Wegovy given its cardiovascular indication from the SELECT trial, but the rule has not been finalized as of this writing.

Medicaid coverage varies by state. As of 2025, a minority of state Medicaid programs cover Wegovy or Zepbound without extensive prior authorization barriers.

The HealthRX GLP-1 Cost Navigation Framework identifies four payer pathways for patients starting therapy in 2025:

1. Diabetes diagnosis with commercial insurance. Ozempic or Mounjaro are typically covered with prior authorization. Expected copay: $25 to $100 per month after manufacturer savings cards.
2. Obesity diagnosis only with commercial insurance. Wegovy or Zepbound require checking the specific formulary for an anti-obesity benefit. If excluded, the Novo Nordisk or Lilly savings card may reduce cost to $0 to $25 per month if the patient meets income and eligibility criteria.
3. Medicare Part D. Brand GLP-1 agents for weight loss are not covered. Patients with type 2 diabetes may access Ozempic or Mounjaro through Part D with standard cost-sharing (manufacturer savings cards are not applicable with government insurance). Compounded semaglutide is an out-of-pocket alternative.
4. Self-pay with no coverage. Zepbound vials via LillyDirect ($349/$499), compounded semaglutide from a 503B pharmacy ($199 to $399), or compounded tirzepatide offer the lowest accessible prices.

What Does Compounded Semaglutide or Tirzepatide Cost?

Compounded GLP-1 medications have become a major cost-reduction pathway since 2022. When the FDA places a drug on its drug shortage list, licensed 503A and 503B pharmacies may legally compound copies using the active pharmaceutical ingredient. Both semaglutide (all branded forms) and tirzepatide have appeared on the FDA shortage list at various points, creating a legal window for compounding.

Compounded semaglutide from a telehealth platform backed by a 503B outsourcing facility typically costs $199 to $399 per month depending on dose. Compounded tirzepatide runs slightly higher, often $350 to $549 per month. These prices include the medication and, in most cases, the prescriber visit and ongoing clinical oversight through the telehealth model.

The FDA removed Wegovy and Ozempic from its shortage list in February 2025, which means 503A and 503B pharmacies were given a compliance deadline to stop compounding semaglutide. That deadline was then subject to legal challenge and court-ordered stays as of mid-2025. Tirzepatide shortage status and compounding eligibility continued to evolve through the same period. Patients considering compounded options should confirm current FDA shortage status with their prescriber before starting.

Quality differences between compounded and branded products are a genuine clinical concern. The FDA has noted that compounded drugs are not FDA-approved and have not undergone the same review for safety, efficacy, and manufacturing quality. However, 503B outsourcing facilities are subject to FDA inspection and current good manufacturing practice (cGMP) requirements, which provides a meaningfully higher quality floor than 503A pharmacies or illicit online sellers.

STEP-3 (N=611) showed that semaglutide 2.4 mg combined with intensive behavioral therapy produced 16.0% mean weight loss at 68 weeks [11]. That result depends on accurate dosing and product integrity, underscoring why pharmacy source matters when brand is unavailable or unaffordable.

How Manufacturer Savings Programs Actually Work

Both Novo Nordisk and Eli Lilly offer patient savings programs, but eligibility rules are specific and the fine print affects real-world access.

Novo Nordisk (Ozempic and Wegovy). The Ozempic savings card caps monthly cost at $25 for commercially insured patients. The Wegovy savings card can bring cost to $0 per month. Both require that the patient have commercial insurance that covers the drug (at any level, including after-deductible). Patients with government-funded insurance (Medicare, Medicaid, TRICARE, VA) are excluded. Income-based assistance is available separately through the NovoCare Patient Assistance Program for uninsured patients below certain income thresholds.

Eli Lilly (Mounjaro and Zepbound). The Mounjaro savings card offers the drug for as low as $25 per month for eligible commercially insured patients. Zepbound savings cards operate similarly. LillyDirect self-pay pricing ($349/$499 for vials) is available to anyone without requiring insurance, making it the most accessible Lilly option for uninsured patients. Lilly's Insulin Value Program model does not apply to GLP-1 agents.

A direct quotation from the Wegovy FDA label (2024 revision) states: "Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition" [4]. This language shapes what insurers are asked to authorize.

The American Association of Clinical Endocrinology's position is direct: "Obesity is a chronic disease that requires lifelong medical attention" [10]. That framing supports coverage arguments when submitting prior authorization appeals, and experienced obesity medicine providers often reference it explicitly in appeal letters.

Cost Comparison: Brand vs. Compounded vs. Vial Options

The table below summarizes 2025 monthly cost across the main access pathways. All brand prices are list (WAC) prices. Compounded ranges reflect observed telehealth platform pricing for 503B-sourced product.

| Medication | List Price/Month | Savings Card (Commercially Insured) | Self-Pay / Vial Option | Compounded Equivalent | |---|---|---|---|---| | Ozempic (semaglutide, any dose) | ~$969 | ~$25 | Not available | Compounded semaglutide: $199, $399 | | Wegovy (semaglutide 2.4 mg) | ~$1,349 | ~$0 | Not available | Compounded semaglutide: $199, $399 | | Mounjaro (tirzepatide, any dose) | ~$1,069 | ~$25 | Not available | Compounded tirzepatide: $350, $549 | | Zepbound (tirzepatide, any dose) | ~$1,059 | ~$25 | $349, $499 (vials, LillyDirect) | Compounded tirzepatide: $350, $549 |

The Zepbound vial pricing through LillyDirect is the most significant structural change in GLP-1 affordability since 2023. For a self-pay patient who can manage vial injections, the $349 entry point for the 2.5 mg or 5 mg dose is close to competitive with compounded tirzepatide and carries the full FDA-approval status.

What Happens to Cost During Dose Escalation?

Dose escalation affects affordability in a practical way that most cost articles overlook. The standard Ozempic titration starts at 0.25 mg weekly for four weeks (not a therapeutic dose, used only to reduce gastrointestinal side effects), then 0.5 mg, then 1 mg, then 2 mg if needed. Each dose-step still costs roughly $969 per month because the pen device design bundles the doses.

Wegovy titrates over 16 weeks from 0.25 mg up to the 2.4 mg maintenance dose. Each titration dose costs approximately the same $1,349 as maintenance. Patients who cannot tolerate escalation above 1.7 mg stay at that dose indefinitely, still paying ~$1,349.

Zepbound and Mounjaro have six dose steps over as many as 20 weeks of titration. LillyDirect vial pricing separates into two tiers: 2.5 mg and 5 mg at $349, and 7.5 mg through 15 mg at $499, which means the self-pay cost rises by $150 per month once the patient crosses the 5 mg threshold. Budgeting for this step is something HealthRX clinicians discuss with patients before they start therapy.

SURMOUNT-3 (N=579) enrolled patients who had already achieved at least 5% weight loss through lifestyle modification before randomizing to tirzepatide or placebo. The tirzepatide group lost an additional 18.4% of body weight at 72 weeks [12]. That finding suggests patients who achieve some initial loss through diet before starting medication may reach therapeutic targets at lower doses, potentially keeping monthly costs in the lower vial tier for longer.

Prior Authorization: How to Improve Approval Odds

Prior authorization (PA) is the single largest administrative barrier to brand GLP-1 access. Approval rates for Wegovy and Zepbound on initial submission run below 50% at many plans. Strategies that improve first-pass approval include the following.

The prescriber should document BMI at the time of the visit using a measured weight, not a self-reported weight. ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity) should appear on the PA form alongside any comorbidity codes (E11 for type 2 diabetes, I10 for hypertension, E78.5 for hyperlipidemia). For Wegovy specifically, the SELECT cardiovascular outcome data from NEJM 2023 [1] can be cited in the appeal if the patient has established cardiovascular disease.

Step therapy requirements are common. Many plans require documented 90-day trials of phentermine/topiramate (Qsymia), naltrexone/bupropion (Contrave), or orlistat before approving a GLP-1. If the patient has already tried one of these, documentation of that trial and either intolerance or inadequate response strengthens the PA submission.

STEP-8 (N=338) showed that semaglutide 2.4 mg produced 15.8% weight loss versus 6.4% with liraglutide 3 mg at 68 weeks [13]. This head-to-head superiority data supports the argument that older, cheaper GLP-1 agents are not therapeutically equivalent to semaglutide 2.4 mg or tirzepatide, which is relevant when a payer tries to substitute liraglutide as a lower-cost alternative.

Generic and Biosimilar Timelines

No FDA-approved generic or biosimilar version of semaglutide or tirzepatide is available in the United States as of 2025. Ozempic's U.S. patent protection is expected to extend through approximately 2032 for the composition-of-matter patent, though Novo Nordisk has additional patents on the delivery device and formulation. Tirzepatide patents run on a similar timeline.

The FDA approved the first semaglutide biosimilar application, but Novo Nordisk has filed patent-infringement suits that are likely to delay launch under the Biologics Price Competition and Innovation Act (BPCIA) 30-month stay. Patients should not expect a true FDA-approved generic at major-chain pharmacy pricing before the early 2030s.

The compounded pathway, for as long as it remains legally available under shortage status, currently represents the closest functional equivalent to generic pricing.